C arotid artery stenosis is a major risk factor for ischemic stroke, 1 and randomized trials conducted in the 1980s to 1990s demonstrated that carotid endarterectomy (CEA) reduced the overall stroke risk for symptomatic and asymptomatic patients with severe carotid stenosis. [2] [3] [4] The relationship between surgeon case-volume and postprocedural outcomes has been examined extensively for CEA, and many have reported that low surgeon case-volume is associated with worse periprocedural outcomes. [5] [6] [7] This is particularly concerning when considering that surgeons participating in trials had shown proficiency in the procedure (eg, average yearlyreimbursements for carotid artery stenting (CAS) as an alternative revascularization procedure for Medicare beneficiaries at high-surgical risk meeting the following criteria: (1) ≥70% symptomatic carotid stenosis, (2) 50% to 70% symptomatic carotid stenosis enrolled in an approved study, or (3) ≥80% asymptomatic carotid stenosis and enrolled in an approved study. 10 Over the following years, the number of CAS procedures performed among Medicare beneficiaries grew, whereas the rate of CEA procedures declined. 11, 12 We hypothesized that the reduction in the overall rate of CEAs in the Medicare beneficiaries may have caused case-volumes of the individual performing surgeons to decline, leading to worse periprocedural outcomes. The objective of this study is to examine the decline in past-year case-volumes of surgeons performing CEA before and after the NCD for CAS and to assess its effect on 30-day post-CEA mortality.
Methods

Data Sources
We used 2000 to 2008 Medicare claims data for all patients who underwent inpatient CEA (ICD-9-CM code: 38.12) or CAS (ICD-9-CM codes: 00.61, 00.63, 00.64). The data comprised administrative claims for fee-for-service beneficiaries accounting for ≈80% of the total Medicare population 13 and provides information on inpatient and outpatient healthcare services covered under Medicare Parts A and B, as well as patient demographics, Medicare enrollment, and date of death.
Study Sample
The study sample consisted of patients undergoing inpatient CEA between 2001 and 2008 or inpatient CAS between 2005 and 2008. We required patients to be at least 66 years of age at the time of the procedure with 365 days of continuous Medicare fee-for-service enrollment. If they underwent multiple carotid revascularizations, we selected the first one. We used CPT-4 code 35301 for CEA and CPT-4 codes 37215 and 37216 (appearing after 2005) for CAS to identify the claims for the performing surgeons. We required these claims to have procedure dates during patients' hospitalization period and excluded all those with modifier codes for procedure assistance. Patients with no identifiable performing surgeon were excluded ( Figure I in the online-only Data Supplement).
Surgeon Case Volume and Subspecialty
We identified surgeons performing CEAs using Unique Physician Identifier Numbers or National Provider Identifiers. When multiple claims for a procedure were available (<0.3%), we randomly selected one of the surgeons. For each CEA procedure, the performing surgeon's past-year case-volume was calculated as the number of CEAs performed during the prior 365 days. Subspecialty information was available from the claims.
Outcome
We assessed all-cause mortality in the 30 days after CEA. We collected data on patients' date of death from Medicare vital status file.
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Patient Characteristics
Using inpatient and outpatient claims and validated algorithms whenever possible, the following comorbidities were identified in the year before the CEA/CAS hospitalization: atrial fibrillation, heart failure, myocardial infarction, diabetes mellitus, hypertension, gastrointestinal bleeding, chronic obstructive pulmonary disease, chronic kidney disease, cancer, depression, and anemia (algorithms in Table I in the online-only Data Supplement). We defined prior ischemic stroke as an ICD-9-CM code of 433.xx (occlusion and stenosis of precerebral arteries), 434.xx (occlusion of cerebral arteries), 436 (acute, but ill-defined, cerebrovascular disease), 437.x (other and ill-defined cerebrovascular disease), or 438.xx (late effects of cerebrovascular disease), and transient ischemic attack (TIA) as an ICD-9-CM code of 435 (transient cerebral ischemia) in the primary or secondary discharge diagnosis during the 180 days preceding the CEA/CAS hospitalization. These algorithms were selected as a result of their high sensitivity to capture strokes in administrative claims data. 15 We also identified patients who underwent coronary artery bypass graft procedures during the hospitalization before or on the same day as CEA or CAS (ICD-9-CM codes 36.1x, 36.2, or V45.81 or CPT-4 codes 33510-33536). Patients were categorized as having undergone elective CEA unless hospital admission type was defined as urgent or emergent. As a measure of overall comorbidity burden, we calculated the Elixhauser comorbidity score, developed as a predictive score for in-hospital death, healthcare costs, and length of hospitalization using administrative data. 16, 17 
Statistical Analysis
We assessed the rate of CEA and CAS procedures (number of procedures per 10 000 Medicare beneficiaries) for each calendar year using the total number of enrollees as the denominator. The rates were standardized to the age, sex, and race distribution of beneficiaries in the most recent year (2008) .
We then assessed the change in characteristics of patients undergoing CEA and performing surgeon specialty over time by aggregating patients into 4 two-year time blocks (2001-2002, 2003-2004, 2005-2006, and 2007-2008 Given that no clinically meaningful or established cut-offs for categorizing the surgeon CEA case-volumes have been reported, we first visually evaluated the relationship between 30-day mortality and continuous surgeon past-year case-volume by fitting a restricted logistic cubic spline regression model using the SAS macro by Spiegelman et al, 18 which allows modeling of smooth nonlinear relationships between a continuous exposure and an outcome while adjusting for other covariates. 19 Using the visualization of the relationship between past-year casevolume and 30-day mortality, we categorized the past-year casevolume into 4 levels. We estimated the rate of 30-day post-CEA mortality overall and by case-volume category in the 4 time blocks. To assess the change in post-CEA 30-day mortality over time, we estimated the relative risk of 30-day mortality in the later time blocks relative to the 2001 to 2002 block, using logistic regression, adjusting for all patient-and surgeon-level measured covariates and surgeon case-volume category. We also estimated the relative risk of 30-day mortality for CEAs performed by surgeons in higher past-year casevolume categories compared with the lowest category in each time block.
All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). The study was approved by Brigham and Women's Hospital's institutional review board. 
Results
Trends in Rates of
Trends in CEA Patient Characteristics
Over the study period, we observed that patients selected for CEA became older and tended to have a higher comorbidity burden over time, with increased proportions of patients with comorbidities including atrial fibrillation, chronic obstructive pulmonary disease, depression and chronic kidney disease, and higher mean Elixhauser comorbidity scores. On the other hand, the proportion of patients with prior stroke, TIA, myocardial infarction slightly decreased and concurrent coronary artery bypass graft and nonelective admissions became less prevalent (Table 1) The logistic regression analysis showed that the increased relative risk of 30-day mortality for low (<10) case-volume surgeons remained significantly higher compared with higher past-year case-volume surgeons, after controlling for patients' demographics, comorbidities and admission type, presence of concurrent coronary artery bypass graft, and the subspecialty of the surgeons. This was true across all time blocks, although results were not all significant. The relative risk of 30-day post-CEA mortality comparing higher versus lowest past-year case-volume surgeons remained fairly constant across the time blocks, despite large reduction in the overall mortality risk (Table 3 ). and 0.3% in Carotid Revascularization Endarterectomy vs Stenting Trial (CREST). [20] [21] [22] The 30-day post-CEA mortality improved slightly overtime, but CEAs performed by lower past-year case-volume surgeons were associated with higher 30-day mortality after adjusting for patients' demographics, comorbidities, hospital admission type, presence of concurrent coronary artery bypass graft and surgeon subspecialty, before and after the 2005 NCD to reimburse CAS.
Standardized rates of CEA declined between 2002 and 2008, but it does not seem that all of these patients were selected for CAS instead of CEA as the increased CAS rate was less than the decline in the CEA rate. This is consistent with recent studies among Medicare beneficiaries, 11, 23, 24 which found a reduction in the overall rate of carotid revascularizations over 2001 to 2007. This may be explained by improved medical management of atherosclerosis in general or carotid stenosis, leading to a reduction in the incidence of asymptomatic or symptomatic carotid stenosis, [25] [26] [27] a perception of reduced relative benefit from carotid revascularization especially in asymptomatic patients, [28] [29] [30] [31] improved or increased use of diagnostic procedures allowing for better patient selection, 24 or dissemination of evidence on the increased periprocedural risks in certain subpopulations. 32 Our results suggest that the association between 30-day post-CEA mortality and surgeon past-year case-volume remained fairly constant before and after the NCD. Overall, 30-day mortality after CEA decreased, despite the fact that patients were older and had a heavier comorbidity burden in the later years of this study, a trend which persisted after controlling for patient characteristics and surgeon case volumes. This may be attributed, in part, to the widespread use of aspirin and statins, which have been shown to improve CEA outcomes, [33] [34] [35] and to general improvement of perioperative hospital care. Among CEA patients with part D coverage in 2007 to 2008, the proportion of patients using statins increased only slightly (Table II in the online-only Data Supplement). We did not have data on drug prescriptions for patients in earlier periods, nor could we reliably capture the use of aspirin throughout the study period as over-the-counter prescriptions are not reimbursed by Part D. This is the first study in the full contemporary fee-forservice elderly Medicare beneficiaries investigating the CEA volume-outcome relationship and the effect of the CAS NCD on surgeon past-year case-volume and 30-day mortality after CEA. One of the major strength of our study is the size of the study sample and its representativeness. We had access to all inpatient and outpatient claims for fee-for-service Medicare patients undergoing inpatient CAS and CEA.
On the other hand, our study should be interpreted in the context of certain limitations. Most importantly, clinical data on some important potential confounders were limited or unavailable. We were unable to assess what proportion of CEA patients met the indication for CAS as per the NCD. We defined symptomatic status as having any hospital ICD9-CM code for strokes and TIAs in the prior 6 months before the procedure. The proportion of symptomatic patients is likely misestimated as the algorithm does not capture stroke/TIAs not resulting in hospitalizations, transient monocular blindness, or stroke/TIAs that lead to hospitalizations during which CEA was performed, and at the same time, as we were unable to distinguish a contralateral event to an ipsilateral event in our data. We also could neither identify patients who were at high surgical risk, nor assess their degree of carotid stenosis. The decline in mortality over time that we observed could therefore be attributed, in part, to the channeling of higher risk patients to CAS, resulting in a lower risk CEA patient pool. If high-volume surgeons are more likely to treat lower risk patients who are not symptomatic as previously suggested, 8 our results would be biased in favor of higher volume surgeons.
We assessed mortality, a hard end point, but did not assess the volume-outcome association for perioperative strokes because postprocedural events were not distinguishable from preprocedural events that lead to hospitalizations in our data. Our study sample consisted of patients covered under the fee-for-service Medicare plan. Although Medicare is the payer for >70% of the CEA procedures nationwide, 
Conclusions
The rate of CEA procedures in the elderly Medicare fee-forservice beneficiaries decreased by ≈30% as did performing surgeon past-year case-volume by ≈20% in the median volume, between 2001 and 2008. The overall 30-day mortality after CEA was 1.3% in our elderly Medicare patients, which was higher than that in the recent randomized clinical trials of CEA versus CAS. Although the mortality improved slightly over time, lower surgeon case-volume was consistently associated with higher 30-day post-CEA mortality before and after the NCD for CAS. The 30-day death, stroke, and MI after CAS and CEA can be used to monitor the quality of these procedures and outcomes in routine clinical practice. Therefore, these data should be widely collected together with relevant clinical risk factors and made available to clinical providers and decision makers in the field to optimize patient selection and applying evidence-based standards on the training and proficiency requirements for the proceduralists. funding agency had no role in the design and conduct of the study, or in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the article, or in the decision to submit the article for publication. 
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